Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura

Critical Reviews in Oncology/Hematology

Volumn 65, Issue 1, 2008, Pages 21-31

  Zhou, Zeping ^a   Yang, Renchi ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

Idiopathic thrombocytopenic purpura; Refractory; Rituximab

Indexed keywords

ALPHA INTERFERON; AMINOCAPROIC ACID; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; DANAZOL; DEXAMETHASONE; DIPHENHYDRAMINE; GLUCOCORTICOID; IMMUNOGLOBULIN; PARACETAMOL; PREDNISONE; RHESUS ANTIBODY; RITUXIMAB; SEROTONIN ANTAGONIST; THROMBOPOIETIN; VINCA ALKALOID;

APOPTOSIS; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CLINICAL EVALUATION; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOREGULATION; INTERSTITIAL PNEUMONIA; LABORATORY DIAGNOSIS; LONG TERM CARE; LUPUS ERYTHEMATOSUS; MOLECULE; MYASTHENIA GRAVIS; NONHODGKIN LYMPHOMA; PREMEDICATION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SPLENECTOMY; THROMBOCYTE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; BLOOD PLATELETS; CHRONIC DISEASE; DRUG RESISTANCE; HUMANS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 36849078877     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2007.06.007     Document Type: Review

References (134)

1. Olsson B., Andersson P.O., Jernas M., et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 9 (2003) 1123-1124
2. Zhou B., Zhao H., Yang R.C., and Han Z.C. Multi-dysfunctional pathophysiology in ITP. Crit Rev Oncol Hematol 54 (2005) 107-116
3. Segal J.B., and Powe N.R. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 4 (2006) 2377-2383
4. Virgolini L., and Marzocchi V. Rituximab in autoimmune diseases. Biomed Pharmacother 58 (2004) 299-309
5. Zeller B., Rajantie J., Hedlund-Treutiger I., et al. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease. Acta Paediatr 94 (2005) 178-184
6. Frederiksen H., and Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 94 (1999) 909-913
7. Provan D., and Newland A. Idiopathic thrombocytopenic purpura in adults. J Pediatr Hematol Oncol 25 Suppl 1 (2003) S34-S38
8. Andersson P.O., and Wadenvik H. Chronic idiopathic thrombocytopenic purpura (ITP): molecular mechanisms and implications for therapy. Expert Rev Mol Med 6 (2004) 1-17
9. Bussel J.B. Novel approaches to refractory immune thrombocytopenic purpura. Blood Rev 16 (2002) 31-36
10. Bussel J.B. Overview of idiopathic thrombocytopenic purpura: new approach to refractory patients. Semin Oncol 27 (2000) 91-98
11. Cines D.B., and McMillan R. Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med 56 (2005) 425-442
12. Stasi R., and Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 79 (2004) 504-522
13. Crow A.R., Song S., Siragam V., and Lazarus A.H. Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia. Pediatr Blood Cancer 47 (2006) 710-713
14. Siragam V., Crow A.R., Brinc D., et al. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 12 (2006) 688-692
15. Kojouri K., and George J.N. Recent advances in the treatment of chronic refractory immune thrombocytopenic purpura. Int J Hematol 81 (2005) 119-125
16. George J.N. Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost 4 (2006) 1664-1672
17. Portielje J.E., Westendorp R.G., Kluin-Nelemans H.C., and Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 97 (2001) 2549-2554
18. McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med 126 (1997) 307-314
19. Marsh J.C., and Gordon-Smith E.C. CAMPATH-1H in the treatment of autoimmune cytopenias. Cytotherapy 3 (2001) 189-195
20. Narang M., Penner J.A., and Williams D. Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab). Am J Hematol 74 (2003) 263-267
21. Kuwana M., Nomura S., Fujimura K., et al. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 103 (2004) 1229-1236
22. McFarland J. Pathophysiology of platelet destruction in immune (idiopathic) thrombocytopenic purpura. Blood Rev 16 (2002) 1-2
23. Savasman C.M., and Sandler S.G. Serologic aspects of treating immune thrombocytopenic purpura using intravenous Rh immune globulin. Immunohematol 17 (2001) 106-110
24. Dunussi-Joannopoulos K., Hancock G.E., Kunz A., et al. B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model. Blood 106 (2005) 2235-2243
25. Harrington W.J., Minnich V., Hollingsworth J.W., and Moore C.V. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 38 (1951) 1-10
26. Silverman G.J., and Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 48 (2003) 1484-1492
27. Sibilia J. Novel concepts and treatments for autoimmune disease: ten focal points. Joint Bone Spine 71 (2004) 511-517
28. Dorner T., and Lipsky P.E. Signalling pathways in B cells: implications for autoimmunity. Curr Top Microbiol Immunol 305 (2006) 213-240
29. Park Y.W., Pryshchep S., Seyler T.M., Goronzy J.J., and Weyand C.M. B cells as a therapeutic target in autoimmune diseases. Expert Opin Ther Targets 9 (2005) 431-445
30. Cooper N., and Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol 133 (2006) 364-374
31. Dorner T. Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. J Rheumatol Suppl 77 (2006) 3-11
32. Yan J., Harvey B.P., Gee R.J., Shlomchik M.J., and Mamula M.J. B cells drive early T cell autoimmunity in vivo prior to dendritic cell-mediated autoantigen presentation. J Immunol 177 (2006) 4481-4487
33. Tian J., Zekzer D., Lu Y., Dang H., and Kaufman D.L. B cells are crucial for determinant spreading of T cell autoimmunity among beta cell antigens in diabetes-prone nonobese diabetic mice. J Immunol 176 (2006) 2654-2661
34. Looney R.J. Treating human autoimmune disease by depleting B cells. Ann Rheum Dis 61 (2002) 863-866
35. Browning J.L. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 5 (2006) 564-576
36. Moulin V., Andris F., Thielemans K., et al. B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med 192 (2000) 475-482
37. Lazarus A.H., Ellis J., Semple J.W., et al. Comparison of platelet immunity in patients with SLE and with ITP. Transfus Sci 22 (2000) 19-27
38. Potter K.N., Mockridge C.I., Rahman A., et al. Disturbances in peripheral blood B cell subpopulations in autoimmune patients. Lupus 11 (2002) 872-877
39. Mackay F., and Browning J.L. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2 (2002) 465-475
40. Emmerich F., Bal G., Barakat A., et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol 136 (2007) 309-314
41. Tsubata T., and Honjo T. B cell tolerance and autoimmunity. Rev Immunogenet 2 (2000) 18-25
42. Azulay-Debby H., and Melamed D. B cell receptor editing in tolerance and autoimmunity. Front Biosci 12 (2007) 2136-2147
43. Tsubata T. B cell abnormality and autoimmune disorders. Autoimmunity 38 (2005) 331-337
44. Grimaldi C.M., Hicks R., and Diamond B. B cell selection and susceptibility to autoimmunity. J Immunol 174 (2005) 1775-1781
45. Noelle R.J., and Erickson L.D. Determinations of B cell fate in immunity and autoimmunity. Curr Dir Autoimmun 8 (2005) 1-24
46. Hultin L.E., Hausner M.A., Hultin P.M., and Giorgi J.V. CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry 14 (1993) 196-204
47. Jazirehi A.R., and Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 24 (2005) 2121-2143
48. Reff M.E., Carner K., Chambers K.S., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 (1994) 435-445
49. McLaughlin P., White C.A., Grillo-Lopez A.J., and Maloney D.G. Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology (Williston Park) 12 (1998) 1763-1769 [discussion 1769-1770, 1775-1767]
50. Cvetkovic R.S., and Perry C.M. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 66 (2006) 791-820
51. Protheroe A., Edwards J., Simmons A., Maclennan K., and Selby P. Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma. Eumatology (Oxford) 38 (1999) 1150-1152
52. Stasi R., Pagano A., Stipa E., and Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98 (2001) 952-957
53. Weide R., Heymanns J., Pandorf A., and Koppler H. Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus 12 (2003) 779-782
54. Looney R.J., Anolik J.H., Campbell D., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50 (2004) 2580-2589
55. Zaja F., Russo D., Fuga G., Perella G., and Baccarani M. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 55 (2000) 1062-1063
56. Okamoto H., and Kamatani N. Rituximab for rheumatoid arthritis. N Engl J Med 351 (2004) 1909 [author reply 1909]
57. Zhang N., Khawli L.A., Hu P., and Epstein A.L. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas. Clin Cancer Res 11 (2005) 5971-5980
58. Vega M.I., Huerta-Yepez S., Jazirehi A.R., Garban H., Bonavida B., and Rituximab. (Chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene 24 (2005) 8114-8127
59. Weng W.K., and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21 (2003) 3940-3947
60. Manches O., Lui G., Chaperot L., et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 101 (2003) 949-954
61. Golay J., Cittera E., Di Gaetano N., et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 91 (2006) 176-183
62. Friedberg J.W. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology Am Soc Hematol Educ Program (2005) 329-334
63. Smith M.R., and Rituximab. (Monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22 (2003) 7359-7368
64. Di Gaetano N., Cittera E., Nota R., et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171 (2003) 1581-1587
65. Harjunpaa A., Junnikkala S., Meri S., and Rituximab. (Anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 51 (2000) 634-641
66. Stanglmaier M., Reis S., and Hallek M. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol 83 (2004) 634-645
67. Byrd J.C., Kitada S., Flinn I.W., et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 99 (2002) 1038-1043
68. Olszewski A.J., and Grossbard M.L. Empowering targeted therapy: lessons from rituximab. Sci STKE 2004 (2004) pe30
69. Alas S., and Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 61 (2001) 5137-5144
70. Goronzy J.J., and Weyand C.M. B cells as a therapeutic target in autoimmune disease. Arthritis Res Ther 5 (2003) 131-135
71. Tokunaga M., Fujii K., Saito K., et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) 44 (2005) 176-182
72. Sfikakis P.P., Boletis J.N., Lionaki S., et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52 (2005) 501-513
73. Gong Q., Ou Q., Ye S., et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174 (2005) 817-826
74. Provan D., Newland A.C., Norfolk D., et al. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 120 (2003) 574-596
75. Aggarwal A., and Catlett J.P. Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura. South Med J 95 (2002) 1209-1212
76. Carbone J., Escudero A., Mayayo M., et al. Partial response to anti-CD20 monoclonal antibody treatment of severe immune thrombocytopenic purpura in a patient with common variable immunodeficiency. Ann NY Acad Sci 1051 (2005) 666-671
77. Zaja F., Iacona I., Masolini P., et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 87 (2002) 189-195
78. Santos E.S., Arosemena L.R., Raez L.E., O'Brien C., and Regev A. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver Int 26 (2006) 625-629
79. Saouli Z., Papadopoulos A., Kaiafa G., et al. Resistant Idiopathic Thrombocytopenic Purpura-treatment with Rituximab. ASH Annu Meet Abstr 108 (2006) 3968
80. Latifzadeh S.Z., and Entezari V. Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report. Clin Appl Thromb Hemost 12 (2006) 489-492
81. Cohen Y., and Polliack A. Sustained complete remission of chronic refractory immune thrombocytopenic purpura (ITP) of 10 years duration after only two infusions of rituximab. Hematol J 3 (2002) 61-62
82. Shvidel L., Klepfish A., and Berrebi A. Successful treatment with Rituximab for relapsing immune thrombocytopenic purpura (ITP) associated with low-grade non-Hodgkin's lymphoma. Am J Hematol 67 (2001) 213-214
83. Delgado J., Bustos J.G., Jimenez-Yuste V., and Hernandez-Navarro F. Anti-CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura. Haematologica 87 (2002) 215-216
84. Koulova L., Alexandrescu D., Dutcher J.P., et al. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases. Am J Hematol 78 (2005) 49-54
85. Ratanatharathorn V., Carson E., Reynolds C., et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 133 (2000) 275-279
86. Narat S., Gandla J., Hoffbrand A.V., Hughes R.G., and Mehta A.B. Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica 90 (2005) 1273-1274
87. Bengtson K.L., Skinner M.A., and Ware R.E. Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura. J Pediatr 143 (2003) 670-673
88. Faurschou M., Hasselbalch H.C., and Nielsen O.J. Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia. Eur J Haematol 66 (2001) 408-411
89. Pusiol A., Cesaro S., Nocerino A., et al. Successful treatment with the monoclonal antibody rituximab in two children with refractory autoimmune thrombocytopenia. Eur J Pediatr 163 (2004) 305-307
90. Roganovic J. Rituximab treatment in refractory idiopathic thrombocytopenic purpura in children. Eur J Pediatr 164 (2005) 334
91. Moschovi M., Trimis G., Pergantou H., et al. Clinical remission following monoclonal anti-CD20 therapy in two children with chronic refractory idiopathic thrombocytopenic purpura. J Paediatr Child Health 41 (2005) 384-386
92. Ahmad H.N., Ball C., Height S.E., and Rees D.C. Rituximab in chronic, recurrent HIV-associated immune thrombocytopenic purpura. Br J Haematol 127 (2004) 607-608
93. Weitz I.C. Treatment of immune thrombocytopenia associated with interferon therapy of hepatitis C with the anti-CD20 monoclonal antibody, rituximab. Am J Hematol 78 (2005) 138-141
94. Trelinski J., Chojnowski K., Kurenko-Deptuch M., et al. Successful treatment of refractory autoimmune thrombocytopenia with rituximab and cyclosporin A in a patient with chronic granulomatous disease. Ann Hematol 84 (2005) 835-836
95. Lalayanni C., Stavroyianni N., Saloum R., Tsompanakou A., and Anagnostopoulos A. Rituximab is effective for selected patients with chronic steroid-refractory immune thrombocytopenic purpura. Hematology 9 (2004) 287-289
96. ten Cate R., Smiers F.J., Bredius R.G., et al. Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus. Rheumatology (Oxford) 43 (2004) 244
97. Kneitz C., Wilhelm M., and Tony H.P. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology 206 (2002) 519-527
98. Thude H., Gruhn B., Werner U., et al. Treatment of a patient with chronic immune thrombocytopenic purpura with rituximab and monitoring by flow cytometric analysis. Acta Haematol 111 (2004) 221-224
99. Riksen N.P., Keuning J.J., and Vreugdenhil G. Rituximab in the treatment of relapsing idiopathic thrombocytopenic purpura. Neth J Med 61 (2003) 262-265
100. Hensel M., and Ho A.D. Successful treatment of a patient with hairy cell leukemia and pentostatin-induced autoimmune thrombocytopenia with rituximab. Am J Hematol 73 (2003) 37-40
101. Russo G., Licciardello M., and La Spina M. Rituximab in children with idiopathic thrombocytopenic purpura: does it really work?. Eur J Pediatr 163 (2004) 569
102. Giagounidis A.A., Anhuf J., Schneider P., et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 69 (2002) 95-100
103. Bennett C.M., Rogers Z.R., Kinnamon D.D., et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 107 (2006) 2639-2642
104. Wang J., Wiley J.M., Luddy R., et al. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr 146 (2005) 217-221
105. Braendstrup P., Bjerrum O.W., Nielsen O.J., et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 78 (2005) 275-280
106. Cooper N., Stasi R., Cunningham-Rundles S., et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 125 (2004) 232-239
107. Saleh M.N., Gutheil J., Moore M., et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 27 (2000) 99-103
108. Taube T., Schmid H., Reinhard H., and von Stackelberg A. Overberg US. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologica 90 (2005) 281-283
109. Penalver F.J., Jimenez-Yuste V., Almagro M., et al. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol 85 (2006) 400-406
110. Cines D.B. Putting the "Tux" on ITP. Blood 107 (2007) 2590-2591
111. Uchida J., Hamaguchi Y., Oliver J.A., et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199 (2004) 1659-1669
112. Zaja F., Vianelli N., Sperotto A., et al. B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 88 (2003) 538-546
113. Anolik J.H., Campbell D., Felgar R.E., et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48 (2003) 455-459
114. McLaughlin P., Hagemeister F.B., and Grillo-Lopez A.J. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 26 (1999) 79-87
115. Onrust S.V., Lamb H.M., and Balfour J.A. Rituximab. Drugs 58 (1999) 79-88 discussion 89-90
116. Swords R., Power D., Fay M., O'Donnell R., and Murphy P.T. Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Am J Hematol 77 (2004) 103-104
117. Burton C., Kaczmarski R., and Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med 348 (2003) 2690-2691 [discussion 2690-2691]
118. van der Kolk L.E., Grillo-Lopez A.J., Baars J.W., Hack C.E., and van Oers M.H. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 115 (2001) 807-811
119. Finazzi G. Rituximab in autoimmune cytopenias: for which patients?. Haematologica 87 (2002) 113-114
120. Cesaro S., Bisogno G., and Pusiol A. Rituximab and factors predictive of response in chronic immune thrombocytopenic purpura of children. J Pediatr 147 (2005) 715 [author reply 715-716]
121. Leandro M.J., Cambridge G., Ehrenstein M.R., and Edwards J.C. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54 (2006) 613-620
122. Kennedy A.D., Beum P.V., Solga M.D., et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 172 (2004) 3280-3288
123. Sashida G., Takaku T.I., Honda S., et al. Granulocyte colony-stimulating factor (G-CSF) could enhance Fcgamma receptor expression in neutrophils of patients with B-cell lymphoma treated with rituximab. Leuk Lymphoma 46 (2005) 789-791
124. Cartron G., Watier H., Golay J., and Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 104 (2004) 2635-2642
125. Clark E.A., and Ledbetter J.A. How does B cell depletion therapy work, and how can it be improved?. Ann Rheum Dis 64 (2005) iv77-iv80
126. Golay J., Lazzari M., Facchinetti V., et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98 (2001) 3383-3389
127. Rose A.L., Smith B.E., and Maloney D.G. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood 100 (2002) 1765-1773
128. Perrotta A.L. Re-treatment of chronic idiopathic thrombocytopenic purpura with rituximab: literature review. Clin Appl Thromb Hemost 12 (2006) 97-100
129. Perez-Calvo J.I., Ruiz-Ruiz F., Amores B., and Torralba M.A. Long-term cost-efficacy of rituximab in immune thrombocytopenic purpura. QJM 98 (2005) 839-840
130. Sandler S.G., and Tutuncuoglu S.O. Immune thrombocytopenic purpura-current management practices. Expert Opin Pharmacother 5 (2004) 2515-2527
131. The American Society of Hematology ITP Practice Guideline Panel. Diagnosis and treatment of idiopathic thrombocytopenic purpura: recommendations of the American Society of Hematology. Ann Intern Med 1997;126:319-26.
132. Perotta A., Sunneberg T., and Scott J. Rituxan in the treatment of chronic idiopathic thrombocytopenic purpura. Blood 94 (1999) 49a [abstract]
133. Stasi R., Stipa E., Forte V., Meo P., and Amadori S. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 99 (2002) 3872-3873
134. Shanafelt T.D., Madueme H.L., Wolf R.C., and Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc 78 (2003) 1340-1346